» Articles » PMID: 31153743

Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population

Overview
Specialty Pulmonary Medicine
Date 2019 Jun 3
PMID 31153743
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Low plasma level of alpha1-antitrypsin (AAT) is an established risk factor for early-onset chronic obstructive lung disease (COPD). However, less attention is given to the levels of AAT in the general population.

Methods: This is a part of a multicentre, population-based study conducted at 11 sites throughout Spain. Plasma levels of AAT were available for 837 persons with a mean (SD) age of 58.05 (11.3) years: 328-smokers, 272-ex-smokers and 237 non-smokers. Out of 837, 303 (36.2%) had a diagnosis of COPD, 222 (26.5%) had respiratory symptoms but no COPD, and 312 (37.3%) were healthy controls.

Results: In the whole cohort, the mean level of plasma AAT was 1.51 (0.47)g/L. Levels were higher in COPD patients [1.55 (0.45)g/L] and individuals with respiratory symptoms [1.57 (0.47)g/L] than in controls [1.43 (0.47)g/L], p<0.001, a finding which persisted after correction for age and CRP. Plasma AAT levels were negatively associated with FEV1/FVC ratio, after adjustment for age, sex, smoking status, CRP, TNFα, fibrinogen and albumin. The risk for COPD was significantly associated with higher AAT levels in univariate and multivariate models, with odds ratios of 1.8 and 1.5, respectively. In the univariate and multivariate models smoking status, gender, and CRP levels were also associated with COPD probability, demonstrating that they act independently.

Conclusion: Increased circulating levels of AAT, similarly to CRP and other markers of systemic inflammation, is an important feature of COPD. Our results highlight a complex interrelationship between levels of AAT and health of respiratory system.

Citing Articles

Biomarkers of chronic airflow limitation and COPD identified by mass spectrometry.

Molin M, Incamps A, Lemasson M, Andersson M, Pertsinidou E, Hogman M ERJ Open Res. 2024; 10(1).

PMID: 38348244 PMC: 10860196. DOI: 10.1183/23120541.00751-2023.


Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study.

Rodriguez Hermosa J, Vargas Centanaro G, Estela Gonzalez Castro M, Miravitlles M, Lazaro-Asegurado L, Jimenez-Rodriguez B Biomedicines. 2023; 11(2).

PMID: 36831051 PMC: 9953718. DOI: 10.3390/biomedicines11020516.


Is there any kind of relationship between alpha-1 antitrypsin levels and lung function parameters?.

Hernandez-Perez J, Lopez-Charry C J Bras Pneumol. 2023; 49(1):e20220432.

PMID: 36790284 PMC: 9970365. DOI: 10.36416/1806-3756/e20220432.


Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry.

Miravitlles M, Turner A, Torres-Duran M, Tanash H, Rodriguez-Garcia C, Lopez-Campos J Respir Res. 2022; 23(1):352.

PMID: 36527073 PMC: 9756677. DOI: 10.1186/s12931-022-02275-4.


Feasibility of a genotyping system for the diagnosis of alpha1 antitrypsin deficiency: a multinational cross-sectional analysis.

Lopez-Campos J, Osaba L, Czischke K, Jardim J, Acquier M, Ali A Respir Res. 2022; 23(1):152.

PMID: 35689213 PMC: 9184812. DOI: 10.1186/s12931-022-02074-x.